Multiple sclerosis: Lessons from neuropathology

Seminars in Neurology

Volumn 18, Issue 3, 1998, Pages 337-349

  Lucchinetti, Claudia F ^a   Brueck, W ^b   Rodriguez, M ^a   Lassmann, H ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Demyelination; Immunopathology; Oligodendrocyte

Indexed keywords

CLINICAL RESEARCH; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW;

EID: 0031770075     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040885     Document Type: Review

References (117)

1. Lumsden CE. The neuropathology of multiple sclerosis. In: Vinken PI, Bruyn GW, eds. Handbook of clinical neurology. New York: Elsevier, 1970:217-309
2. Prineas JW. The neuropathology of multiple sclerosis. In: JC Koetsier, ed. Handbook of clinical neurology. Vol 47. Demyelinating diseases. New York: Elsevier Science, 1985:337-395
3. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274
4. Krucke W. On the histopathology of acute hemorrhagic leukoencephalitis, acute disseminated encephalitis, and concentric sclerosis. In: International symposium on aetiology and pathogenesis of demyelinating diseases, 1973
5. Siemerling E, Raecke E. Beitrag zur klinik und pathologie der multiplen sklerose mit besonderer berucksightigung ihrer pathogenese. Arch Psychiatr Nervenkr 1914;53:385-564
6. Fraenkel M, Jakob A. Zur pathologie der multiplen sklerose mit besonderer berucksighting der akuten formem. Z Neurol 1913; 14:565-603
7. Marburg O. Die sogenannte "akute multiple sklerose." Jahrb Psychiatrie 1906;27:211-312
8. Johnson D, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg type. J Neurol Neurosurg Psychiatry 1990;53:918-921
9. Banerjee A, Chopra J, Kumar B. Acute multiple sclerosis: Report of a case with neuropathological and chemical studies. Neurol India 1977;25:233-237
10. Balo J. Encephalitis perazialis concentrica. Arch Neurol 1928; 19:242-263
11. Kuroiwa Y. Handbook of neurology. Amsterdam: Elsevier, 1985: 409-417
12. Devic C. Myelite subaigue complique de nevrite optique. Bull Med 1894;5:18-30
13. Mandler R. Devic's neuromyelitis optica: A clinicopathological study of eight patients. Ann Neurol 1993;34:162-168
14. Jeffrey A, Buncic J. Pediatric Devic's neuromyelitis optica. J Periatr Ophthalmol Strabismus 1996;33:223-229
15. Alcock N, Hoffman. Recurrent encephalomyelitis in childhood Arch Dis Childhood 1962;37:40-44
16. Hart M, Earle K. Haemorrhagic and perivenous encephalitis: A clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975;38:585-591
17. Hurst E. Acute haemorrhagic leucoencephalitis: A previous undefined entity. Med J Aust 1941;2:1-6
18. Shintaku M, Hirano A, Llena JF. Increased diameter of demyelinated axons in chronic multiple sclerosis of the spinal cord. Neuropathol Appl Neurobiol 1988;14:505
19. Prineas JW, Kwon EE, Cho ES, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis. Ann NY Acad Sci 1984;436:11-32
20. Moore GR, Raine CS. Immunogold localization and analysis of IgG during immune-mediated demyelination. Lab Invest 1988; 59:641-648
21. Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994;121:125-131
22. Prineas JW, Graham JS. Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149-158
23. Lassmann H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Schriftenr Neurol 1983;25:1-135
24. Guo YP, Gao SF. Concentric sclerosis. In: Tyrer JH, Eadie MJ, eds. Proceedings of the Australian Association of Neurologists. Vol 19. Sydney: Adis Health Science Press, 1983:67-76
25. Kirk J. The fine structure of the CNS in multiple sclerosis. Vesicular demyelination in an acute case. Neuropathol Appl Neurobiol 1979;5:289-294
26. Lassmann H, Brunner C, Bradl M, Linigton C. experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determine size and structure of demyelinated lesions. Acta Neuropathol (Berl) 1988;75:566-576
27. Ludwin SK, Johnson ES. Evidence of a "dying-back" gliopathy in demyelinating disease. Ann Neurol 1981;9:301-305
28. Rodriguez M. Virus-induced demyelination in mice: "Dying-back" of oligodendrocytes. Mayo Clin Proc 1985;60:433-438
29. Rodriguez M, Scheithauer BW. Ultrastructure of multiple sclerosis. Ultrastructural Pathol 1994;18:3-13
30. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-636
31. Prineas J. Pathology of the early lesion in multiple sclerosis. Hum Pathol 1975;6:531-554
32. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis. Remyelination of nascent lesions. Ann Neurol 1993;33:137-151
33. Prineas JW, Kwon EE, Goldenberg PZ, et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 1989;61:489-503
34. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis: Oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 1981;45:534-546
35. Selmaj K, Brosnan CF, Raine CS. Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: Implications for multiple sclerosis. Neurology 1992;42:795-800
36. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117:1311-1322
37. Brueck W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994;35: 65-73
38. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. Dual label immunocytochemistry of the active multiple sclerosis lesion: Major histocompatibility complex and activation antigens. Ann Neurol 1988;24:523
39. Sobel RA, Hafler DA, Castro EE, Morimoto C, Weiner HL. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions. J Immunol 1988;140:2210
40. Boyle EA, McGeer PL. Cellular immune response in multiple sclerosis plaques. Am J Pathol 1990;137:575
41. Cuzner ML, Hayes GM, Newcombe J, Woodroofe MN. The nature of inflammatory components during demyelination in multiple sclerosis. J Neuroimmunol 1988;20:203
42. Sobel RA. T lymphocyte subsets in MS lesions. Res Immunol 1989;140:208
43. Raine CS. The Dale E McFarlin memorial lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 1994;36:S61-S72
44. Esiri MM: Multiple sclerosis: A quantitative and qualitative study on immunoglobulin-containing cells in the central nervous system. Neuropath Appl Neurobiol 1980;6:9
45. Mussini JM, Hauw JJ, Escourolle R. Immunofluorescence studies of intracytoplasmic immunoglobulin binding lymphoid cells (CICL) in the central nervous system. Report of 32 cases including 19 MS. Acta Neuropathol (Berl) 1977;40:227
46. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques: an immunocytological study. Brain 1991; 114:557-572
47. Esiri MM, Reading MC. Macrophage populations associated with multiple sclerosis plaques. Neuropathol Appl Neurobiol 1987;13:451-465
48. Brück W, Porada P, Poser S, et al. Monocyte/Macrophage Differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38:788-796
49. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996;6:243-257
50. Canella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435
51. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990;136:1309-1316
52. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97
53. Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol 1989:135-161
54. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993;331:243
55. Traugott U. Multiple sclerosis: Relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol 1987;15:283
56. Brosnan CF, Battistini L, Gao YL, Raine CS, Aquino DA. Heat shock proteins and multiple sclerosis: A review. J Neuropath Exp Neurol 1996;55:389-402
57. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by nonradioactive in situ hybridization. Cytokine 1993;5:583-588
58. Schluesener HJ, Meyermann R. Intercrines in brain pathology. Expression of intercrines in multiple sclerosis and Morbus Creutzfeldt-Jacob lesion. Acta Neuropathol (Berl) 1993;86: 393-396
59. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis. Distribution of T cells. T cell subsets, and Ia-positive macrophages in lesions of different ages J Neuroimmunol 1983;4:201-221
60. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II on macrophages and microglia but not astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-146
61. Raine CS. Multiple sclerosis: Immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994;53:328-337
62. Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edinburgh 1916;50:517-740
63. Linsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994;36:183-189
64. Barkhof F, Thompson AJ, Hodgkinson S, et al. Double-blind placebo-controlled MR monitored exploratory trial of chimeric anti-CD4 antibodies in NS (abstract). J Neuroimmunol 1995;1(suppl):15
65. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-199
66. Schmidt S, Linington C, Zipp F, et al. Multiple sclerosis: Comparison of the human T cell response to S100β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 1997;120:1437-1445
67. van Noort JM, van Sechel AC, Bajramovic JJ, et al. A novel candidate autoantigen in multiple sclerosis: αB-crystallin, a small heat shock protein. Nature 1996;375:798-801
68. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996;85:299-302
69. Birch MK, Barbosa S, Blumhardt LD, O'Brien C, Harding SP. Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis. Arch Ophthalmol 1996;114:34-39
70. Berger T, Weerth S, Kojima K, Linigton C, Wekerle H, Lassmann H. Experimental autoimmune encephalomyelitis: The antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997;76:355-364
71. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendrocyte protein and 2′,3′- cyclic nucleotide 3′-phophodiesterase in the CNS of adult rats. J Neurochem 1989;52:296-304
72. Gardinier MV, Amiguet P, Linigotn C, Matthieu J-M. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res 1992;33: 177-187
73. Johns TG, Kerlero de Rosbo N, Menon KK, Abo S, Gonzales MF, Bernard CCA. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis J Immunol 1995;154:5536-5541
74. Adelmann M, Wood J, Benzel I, et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27
75. Amor S, Groome N, Linigton C, et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biossi AB/H mice. J Immunol 1994;153:4349-4356
76. Bradl M, Linigton C. Animal models of demyelination. Brain Pathol 1996;6:404-311
77. Storch MK, Piddlesden S, Haltia M, Iivaninen M, Morgan P, Lassmann H. Multiple sclerosis: In situ evidence for antibody and complement mediated demyelination. Ann Neurol (in press)
78. Chiang C-S, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996; 97:1512-1524
79. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system specific expression of tumor necrosis factor a. Proc Natl Acad Sci USA 1995;92:11294-11298
80. Selmaj K., Raine CS. Tumor necrosis factor mediates myelin damage in organoptic cultures of nervous tissue. Ann NY Acad Sci 1988;540:568-570
81. Jenkins HG, Ikeda H. Tumor necrosis factor causes an increase in the axonal transport of protein and demyelination in the mouse optic nerve. J Neurol Sci 1992;108:99-104
82. McCallum K, Esiri MM, Tourtellotte WW, Booss J. T cell subsets in multiple sclerosis: Gradients at plaque borders and differences in nonplaque regions. Brain 1987;110:1297-1308
83. Grenier Y, Ruijs TC, Robitaille Y, Olivier A, Antel JP. Immunohistochemical studies of adult human glial cells. J Neuroimmunol 1989;21:103-115
84. Tsuchida T, Parker KC, Turner RV, McFarland HF, Coligan JE, Biddison WE. Auoreactive CD8+ T cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 1994;91:10859-10863
85. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci 1995;15:7293-7300 1996
86. Dowling P, Shang G, Raval S, Menonna J, Couk S, Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1618
87. D'Souza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184:2361-2370
88. Freedman MS, Ruijs TCG, Selin LK, Antel JP. Peripheral blood γδ T cells lyse fresh human brain-derived oligodendrocytes. Ann Neurol 1991;30:794-797
89. Brosnan CF, Battistini L, Gao Y-L, Raine CS, Aquino DA. Heat shock proteins and multiple sclerosis. J Neuropath Exp Neurol 1996;55:389-402
90. Selmaj KW, Brosnan CF, Raine CS. Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: Implications for multiple sclerosis. Neurology 1992;42:795-800
91. Selmaj K, Brosnan CF, Raine CS. Colocalization of lymphocytes bearing gamma delta T cell receptor and heat shock protein hsp65 oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 1991;88:6452-6456
92. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho E. Multiple sclerosis: Pathology of recurrent lesions. Brain 993; 116:681-693,
93. Fazakerley JK, Buchmeier MJ. Pathogenesis of virus-induced demyelination. Adv Virus Res 1993;42:249-324
94. Dal Canto MC, Melvolv RW, Kim BS, Miller SD. Two models of multiple sclerosis: Experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Micro Res Tech 1995;32:215-229
95. Brahic M, Stroop WG, Baringer JR. Theiler's virus persists in glial cells during demyelinating disease. Cell 1981;26:123-128
96. Roos RP, Wollmann R. DA strain of Theiler's murine encephalomyelitis virus induces demyelination in nude mice. Ann Neurol 1984;15:494-499
97. Yamada M, Zurbriggen A, Fujinami RS. Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. J Exp Med 1990;171:1893-1907
98. Yamada M, Zurbriggen A, Fujinami S. The relationship between viral RNA, myelin-specific mRNAs and demyelination in central nervous system disease during Thieler's virus infection. Am J Pathol 1990;137:1467-1479
99. Rosenthal A, Fujinami RS, Lampert PW. Mechanism of Theielr's virus-induced demyelination in nude mice. Lab Invest 1986; 54:515-522
100. Rodriguez M, Leibowitz JL, Lampert PW. Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol 1983;13:426-433
101. Rodriguez M, Prayoonwiwat N, Howe C, Sanborn K. Proteolipid protein gene expression in demyelination and remyelination of the central nervous system. A model for multiple sclerosis. J Neuropathol Exp Neurol 1994;53:136-143
102. Yamada M, Zurbriggen A, Fujinami RS. Monoclonal antibody to Theiler's murine encephalomyelits virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. J Exp Med 1990; 171:1893-1908
103. Zimprich F, Winter J, Wege H. Lassmann H. Coronavirus induced primary demyelination: Indications for the involvement of a humoral immune response. Neuropathol Appl Neurobiol 1991:469-474
104. Carrigan DR, Harrington D, Knox KK. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis. Neurology 1996;47:145-148
105. Sanders VJ, Waddell AE, Felisan SL, Li X, Conrad AJ. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch Neurol 1996;53:123-124
106. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995;92:7440-7444
107. Feigin I, Popoff N. Regeneration of myelin in multiple sclerosis. Neurology 1966;16:364-372
108. Ludwin SK. Remyelination in the central nervous system and peripheral nervous system. Adv Neurol 1988;47:215-254
109. Schlesinger H. Zur Frahe der akuten multiplen Sklerose und der encephalomyelitis disseminata im Kindesalter. Arb Neurol Inst (Wien) 1909;17:410-432
110. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988;333:562-565
111. McKinnn RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990;5:603-614
112. McMorris FA, Mozell RL, Carson MJ, Shinar Y, Meyer RD, Marchetti N. Regulation of oligodendrocyte development and central nervous system myelination by insulin-like growth factors. Ann NY Acad Sci 1993;692:321-334
113. D'Souza SD, Almauskas KA, Antel JP. Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury. J Neurosci Res 1996;43:289-298
114. Liu X, Yao DL, Webster HD. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler 1996;1:2-9
115. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995;92:6190-6194
116. Miller DJ, Sanborn KS, Katzman JA, Rodriguez M. Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci 1994;14:6230-6238
117. Miller DJ, Rodriguez M. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J Immunol 154:2460-2469